Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study

Abstract Monocyte chemoattractant protein-1 (MCP-1, also known as chemokine CCL2) is a vital chemokine that mediates inflammation in Alzheimer’s disease (AD). We analyzed the associations between the baseline plasma MCP-1 level, longitudinal cognitive changes, and genetic effects of CCL2 rs1024611 a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wei-Ju Lee, Yi-Chu Liao, Yen-Feng Wang, I-Feng Lin, Shuu-Jiun Wang, Jong-Ling Fuh
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0ca372facf664fdd8d0e0351892fe418
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0ca372facf664fdd8d0e0351892fe418
record_format	dspace
spelling	oai:doaj.org-article:0ca372facf664fdd8d0e0351892fe4182021-12-02T15:09:05ZPlasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study10.1038/s41598-018-19807-y2045-2322https://doaj.org/article/0ca372facf664fdd8d0e0351892fe4182018-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-19807-yhttps://doaj.org/toc/2045-2322Abstract Monocyte chemoattractant protein-1 (MCP-1, also known as chemokine CCL2) is a vital chemokine that mediates inflammation in Alzheimer’s disease (AD). We analyzed the associations between the baseline plasma MCP-1 level, longitudinal cognitive changes, and genetic effects of CCL2 rs1024611 and its receptor, CC-chemokine receptor 2 (CCR2) rs1799864, in AD. In total, 310 AD patients and 66 mild cognitive impairment (MCI) patients were followed for 2 years, and 120 controls were recruited at baseline for comparison. After adjusting for covariates using one-way analysis of covariance, AD patients had higher plasma MCP-1 levels compared with MCI patients and controls, and severe AD patients had the highest levels. After adjusting for covariates using generalized estimating equation analysis, the results showed that the baseline MCP-1 level was significantly correlated with changes in the two-year Mini-Mental Status Examination (p = 0.046). The A allele of CCR2 rs1799864 was associated with a higher MCP-1 level in AD and MCI patients. In conclusion, plasma MCP-1 might reflect the risk and disease course of AD. A higher plasma MCP-1 level is associated with greater severity and faster cognitive decline. Additionally, the CCR2 polymorphism may play a role in the regulation of MCP-1/CCR2 signaling in AD.Wei-Ju LeeYi-Chu LiaoYen-Feng WangI-Feng LinShuu-Jiun WangJong-Ling FuhNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-8 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Wei-Ju Lee Yi-Chu Liao Yen-Feng Wang I-Feng Lin Shuu-Jiun Wang Jong-Ling Fuh Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study
description	Abstract Monocyte chemoattractant protein-1 (MCP-1, also known as chemokine CCL2) is a vital chemokine that mediates inflammation in Alzheimer’s disease (AD). We analyzed the associations between the baseline plasma MCP-1 level, longitudinal cognitive changes, and genetic effects of CCL2 rs1024611 and its receptor, CC-chemokine receptor 2 (CCR2) rs1799864, in AD. In total, 310 AD patients and 66 mild cognitive impairment (MCI) patients were followed for 2 years, and 120 controls were recruited at baseline for comparison. After adjusting for covariates using one-way analysis of covariance, AD patients had higher plasma MCP-1 levels compared with MCI patients and controls, and severe AD patients had the highest levels. After adjusting for covariates using generalized estimating equation analysis, the results showed that the baseline MCP-1 level was significantly correlated with changes in the two-year Mini-Mental Status Examination (p = 0.046). The A allele of CCR2 rs1799864 was associated with a higher MCP-1 level in AD and MCI patients. In conclusion, plasma MCP-1 might reflect the risk and disease course of AD. A higher plasma MCP-1 level is associated with greater severity and faster cognitive decline. Additionally, the CCR2 polymorphism may play a role in the regulation of MCP-1/CCR2 signaling in AD.
format	article
author	Wei-Ju Lee Yi-Chu Liao Yen-Feng Wang I-Feng Lin Shuu-Jiun Wang Jong-Ling Fuh
author_facet	Wei-Ju Lee Yi-Chu Liao Yen-Feng Wang I-Feng Lin Shuu-Jiun Wang Jong-Ling Fuh
author_sort	Wei-Ju Lee
title	Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study
title_short	Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study
title_full	Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study
title_fullStr	Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study
title_full_unstemmed	Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study
title_sort	plasma mcp-1 and cognitive decline in patients with alzheimer’s disease and mild cognitive impairment: a two-year follow-up study
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/0ca372facf664fdd8d0e0351892fe418
work_keys_str_mv	AT weijulee plasmamcp1andcognitivedeclineinpatientswithalzheimersdiseaseandmildcognitiveimpairmentatwoyearfollowupstudy AT yichuliao plasmamcp1andcognitivedeclineinpatientswithalzheimersdiseaseandmildcognitiveimpairmentatwoyearfollowupstudy AT yenfengwang plasmamcp1andcognitivedeclineinpatientswithalzheimersdiseaseandmildcognitiveimpairmentatwoyearfollowupstudy AT ifenglin plasmamcp1andcognitivedeclineinpatientswithalzheimersdiseaseandmildcognitiveimpairmentatwoyearfollowupstudy AT shuujiunwang plasmamcp1andcognitivedeclineinpatientswithalzheimersdiseaseandmildcognitiveimpairmentatwoyearfollowupstudy AT jonglingfuh plasmamcp1andcognitivedeclineinpatientswithalzheimersdiseaseandmildcognitiveimpairmentatwoyearfollowupstudy
_version_	1718387919195996160

Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study

Ejemplares similares